What is the pregnancy risk classification for azathioprine in a pregnant woman with pemphigus vulgaris?

Azathioprine Pregnancy Risk Category in Pemphigus Vulgaris

Azathioprine is classified as FDA Pregnancy Category D, meaning there is positive evidence of fetal risk, but the benefits may outweigh the risks in life-threatening or serious disease such as pemphigus vulgaris. 1

FDA Classification and Official Warnings

The FDA explicitly states that azathioprine can cause fetal harm when administered to pregnant women and should not be given during pregnancy without careful weighing of risk versus benefit. 1 The drug is teratogenic in animal studies (rabbits and mice) at doses equivalent to human therapeutic doses (5 mg/kg daily), causing skeletal malformations and visceral anomalies. 1

Clinical Evidence in Pemphigus Vulgaris During Pregnancy

Despite the Category D classification, the British Association of Dermatologists guidelines state that azathioprine combined with corticosteroids has been used successfully in pemphigus during pregnancy with relatively low teratogenicity risk. 2, 3, 4 The literature is inconclusive on teratogenic effects in humans, and most investigators have found azathioprine to be relatively safe in pregnancy, particularly in transplant recipients where it is not associated with increased congenital defects (though premature birth and small-for-dates babies are more common). 2

Documented Fetal Risks

The Swedish Medical Birth Register study found a moderately increased risk of congenital malformations (6.2% vs 4.7% in unexposed infants), with a specific association with ventricular/atrial septal defects (adjusted OR: 3.18). 5 Exposed infants were also more likely to be preterm, weigh <2500 gm, and be small for gestational age. 5

Postmarketing reports document intrahepatic cholestasis of pregnancy (ICP) in women treated with azathioprine during pregnancy, which improved following discontinuation. 1 Limited immunologic abnormalities have occurred in some infants, including documented lymphopenia, diminished IgG and IgM levels, CMV infection, and decreased thymic shadow, though most features normalized by 10 weeks postpartum. 1

Risk-Benefit Decision Algorithm for Pemphigus Vulgaris

The general consensus is to limit azathioprine use in pregnancy to those with severe pemphigus disease, particularly when there is no safer alternative treatment. 2

When to Consider Azathioprine:

• Severe pemphigus vulgaris that cannot be controlled with prednisolone alone 2, 3, 4
• When corticosteroid doses required for disease control exceed safe pregnancy limits (>20 mg/day prednisolone long-term) 4
• After intravenous immunoglobulin (IVIg) has been considered or trialed, as IVIg is safer during pregnancy 3, 4

Safer Alternatives to Prioritize First:

• Prednisolone is first-line, with 90% placental inactivation minimizing fetal exposure 4
• IVIg is safe in pregnancy and has demonstrated efficacy in severe pemphigus cases 3, 4
• Superpotent topical corticosteroids for localized disease 4

Comparative Safety: Azathioprine vs Other Immunosuppressants

Azathioprine is significantly safer than mycophenolate mofetil (MPA) during pregnancy. A retrospective cohort study found MPA exposure during early pregnancy was associated with a 2-fold increase in pregnancy loss risk compared to azathioprine (49.5% vs 24.0%; adjusted RR: 1.9). 6 All common pemphigus treatments including mycophenolate mofetil and methotrexate should be avoided during pregnancy, but azathioprine may be used when necessary. 7

Practical Management Recommendations

Ideally, achieve a period of remission with minimal or no therapy before conception to reduce the risk of disease flare-up, at least in the first trimester. 7 This approach allows lower cumulative doses and prevents possible congenital abnormalities from treatment. 7

If azathioprine must be used during pregnancy for severe pemphigus vulgaris:

• Counsel the patient about the potential hazard to the fetus, including the moderately increased risk of cardiac septal defects and growth restriction 1, 5
• Monitor for intrahepatic cholestasis of pregnancy and discontinue azathioprine if ICP develops 1
• Combine with the lowest effective dose of prednisolone to minimize total immunosuppression 2, 3
• Arrange combined dermatology-obstetric care, as pemphigus is associated with fetal growth restriction and prematurity 4

Common Pitfalls to Avoid

• Do not use azathioprine for mild pemphigus that can be controlled with topical corticosteroids and low-dose prednisolone alone 4
• Do not assume azathioprine is contraindicated in all pregnancy cases; in severe pemphigus vulgaris, the maternal disease risk may outweigh fetal risks 2, 1
• Do not overlook IVIg as a safer alternative before escalating to azathioprine 3, 4
• Do not forget to counsel about the 45% risk of transient neonatal pemphigus from transplacental antibody transfer, which resolves within 4 weeks 8, 4